Clinical Significance and Functional Insights of Tesmin in Hepatocellular Carcinoma

Table 2

Overall survival by Kaplan–Meier analyses.

Variables	Patients	Overall survival months		value
	(n = 128)	3-year OS (%)	Mean ± S.D.
Age
<50 yrs	76	37.2	30.7 ± 2.8	0.317
≥50 yrs	52	46.7	35.9 ± 4.0
Sex
Female	33	26.4	25.2 ± 2.7	0.065
Male	95	47.0	35.9 ± 2.9
HBV infection
Negative	41	43.2	34.5 ± 4.0	0.466
Positive	87	36.7	31.7 ± 2.8
AFP level
<400 ng/mL	44	57.4	37.3 ± 3.7	0.146
≥400 ng/mL	84	33.6	30.5 ± 2.8
Lesion number
Single	90	51.0	37.9 ± 2.9	<0.001
Multiple	38	17.5	20.2 ± 2.6
Tumor size
<5.0 cm	76	55.0	39.1 ± 3.2	0.002
≥5.0 cm	52	21.6	24.5 ± 3.1
Tumor side
Unilateral	113	44.0	34.8 ± 2.5	<0.001
Bilateral	15	26.7	11.4 ± 2.0
Pathological grade
Grade 1-2	91	46.5	35.6 ± 2.8	0.060
Grade 3	37	27.9	26.8 ± 4.2
Histological differentiation
Well/moderate	64	41.0	31.8 ± 3.1	0.658
Poor/undifferentiated	64	41.1	33.8 ± 3.3
Resection margin
≥1.0 cm	44	45.6	36.4 ± 4.2	0.406
<1.0 cm	84	39.2	30.7 ± 2.6
Portal vein invasion
Negative	96	48.7	36.9 ± 2.6	<0.001
Positive	32	0	15.6 ± 2.0
TNM stage
TNM I-II	57	70.1	49.9 ± 3.1	<0.001
TNM III-IV	71	17.7	17.7 ± 1.7
Tesmin expression
Low	54	64.9	45.1 ± 3.6	<0.001
High	74	20.7	22.1 ± 2.2

Note. Statistically significant by log-rank test.